Concord Biotech

Concord Biotech, established in 2000, stands as a leading biopharmaceutical entity focused on the specialized production of fermentation-based Active Pharmaceutical Ingredients (APIs) and advanced, high-quality pharmaceutical formulations. Leveraging more than 25 years of dedicated industry experience, the company prioritizes robust research and development initiatives to consistently deliver dependable pharmaceutical solutions aimed at enhancing patient outcomes worldwide.

The company operates with a workforce of 500-1,000 employees across its 2 identified locations, demonstrating a significant operational footprint. Concord Biotech further amplifies its service offerings through comprehensive Contract Development and Manufacturing Services (CDMO), underpinned by substantial technical expertise and adherence to stringent global regulatory approvals. This allows them to effectively serve a diverse international customer base, comprising over 250 global clients spanning 70 countries. Meet Concord Biotech's team to gain insights into their skilled personnel and organizational structure.

Financially, Concord Biotech reported a substantial revenue of $686.0M. Its growth trajectory is further supported by strategic financial backing, including a significant private equity investment of $70.8M received on July 5, 2016, from Quadria Capital. The company's unwavering commitment to innovation is evident as it continuously strives to establish new industry benchmarks within the competitive pharmaceutical sector, solidifying its global market presence. Explore financial highlights for a deeper dive into their fiscal performance and investment history.